doi: 10.3858/emm.2010.42.8.057 110 DavisJBurrARDavisGFBirnbaumerLMolkentinJD
We grant you a personal, non-exclusive, non-transferable license to access CaliforniaPetPharmacy.com and to use the information and services contained on the website subject to your compliance with these Terms
Eighty two percent of previously treated patients received the recommended phase II dose of 160 mg twice daily, and 98% of previously untreated patients received 160 mg twice daily.[13] For patients with RET -altered MTC who were previously treated with vandetanib or cabozantinib: The objective response rate was 69% (95% CI, 55%81%)
If you experience any serious side effects, such as severe abdominal pain, persistent vomiting, or signs of an allergic reaction (rash, itching, swelling, difficulty breathing), seek medical attention immediately